Dr. Medford is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
55 Fruit St
Boston, MA 02114Phone+1 617-643-0596Fax+1 617-643-6443
Education & Training
Massachusetts General HospitalResidency, Internal Medicine, 2017 - 2019
Johns Hopkins University School of MedicineClass of 2015
Certifications & Licensure
MA State Medical License 2016 - 2026- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Integrating machine learning-predicted circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in metastatic breast cancer: A proof of principle study on endo...Lorenzo Gerratana, Andrew A Davis, Lorenzo Foffano, Carolina Reduzzi, Tania Rossi
Cancer Letters. 2025-01-28 - Transdifferentiation of Secretory Carcinoma to Metaplastic Carcinoma at Metastatic Site.Baris Boyraz, Arielle Medford, Amy Ly, Ivan Chebib
International Journal of Surgical Pathology. 2024-12-12 - Deficits of Molecular Prognosis/Diagnosis Studies in Underserved Populations.Arielle J Medford, Beverly Moy
JCO Oncology Practice. 2024-11-01
Press Mentions
Identifying Opportunities to De-Escalate Adjuvant Therapy in Localized HER2+ Breast CancerMay 23rd, 2023- Educated Affected Person® Metastatic Breast Most Cancers Summit HER2 and Triple-Unfavorable Illness Panel: November 12, 2022November 26th, 2022
CDK 4/6 Inhibitor, Ribociclib, with Adjuvant Endocrine Therapy for ER-Positive Breast Cancer (LEADER)April 2nd, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
